Article: 'Zomig' Nasal Spray Provides Relief in Adolescent Migraine.

PHILADELPHIA, Pennsylvania, June 24 /PRNewswire/ -- New clinical trial data presented today at the 47th American Headache Society Annual Scientific meeting shows that zolmitriptan ('Zomig') 5 mg nasal spray is highly effective and well tolerated in the acute treatment of adolescent migraine(1).

Results of the study show that zolmitriptan nasal spray has significantly higher headache response than placebo after one hour (58.1% vs. 43.3%; p

Dr Paul Winner from the Palm Beach Headache Centre, Florida commented, "These results are very significant for the future management of migraine, as we now have conclusive evidence that migraine in adolescents can be ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!